Screener
Edgewise Therapeutics, Inc. EWTX Business Segments — Other General Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherGeneralExpense.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Contracted research expense | $23,942 | $21,298 |
| Personnel expense | 14,725 | 10,624 |
| Stock-based compensation expense | 8,715 | 9,059 |
| Other segment expense(a) | 6,196 | 4,464 |
| Depreciation | 537 | 514 |
| Segment net loss | (54,115) | (45,959) |
| Reconciliation of net loss | ||
| Interest income | 5,102 | 5,161 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s business segments — other general expense?
- Edgewise Therapeutics, Inc. (EWTX) reported business segments — other general expense of $6.2M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s business segments — other general expense changed year-over-year?
- Edgewise Therapeutics, Inc.'s business segments — other general expense increased by 38.8% year-over-year, from $4.46M to $6.2M.
- What does business segments — other general expense mean?
- Includes miscellaneous administrative and operational costs that do not fall under specific research or labor categories. This metric captures the baseline overhead required to sustain corporate functions and general business operations. Tracking this helps identify trends in administrative efficiency and corporate cost control.
Ask your AI about Edgewise Therapeutics, Inc.'s business segments — other general expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude